Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab or Triamcinolone as Adjunct to PRP for PDR
NCT00445003Phase 3Completed
- Sponsor
- Jaeb Center for Health Research
- Start
- Mar 2007
- Primary completion
- Oct 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab, triamcinolone in proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), sponsored by Jaeb Center for Health Research. Started Mar 2007; status: completed.
02
Drugs
ranibizumabtriamcinolone
03
Conditions
proliferative diabetic retinopathy (PDR)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00445003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00445003.